Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb

Terray Therapeutics announced on December 3, 2025 that it achieved a discovery milestone in its multi-target collaboration with Bristol Myers Squibb (NYSE: BMY).

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Success demonstrates the power of EMMI, Terray’s proprietary AI platform integrated with its rapidly expanding 13B+ target-ligand binding database and highly automated lab

LOS ANGELES--(BUSINESS WIRE)-- Terray Therapeutics (www.terraytx.ai), a chemistry-first, AI-native biotech company, today announced the achievement of a discovery milestone in the company’s multi-target collaboration with Bristol Myers Squibb (NYSE: BMY).

Terray’s EMMI platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. The company’s iterative approach integrates AI with an extensive library of quantitative, purpose-built, structure activity data to find the right molecules to solve complex problems in drug discovery.

“Our AI-driven platform discovers and optimizes novel molecules for the difficult-to-drug targets—the ones with no chemistry starting point,” said Jacob Berlin, CEO, Terray Therapeutics. “We are excited about our success together and look forward to further progressing our discovery efforts.”

Terray and BMS are collaborating to accelerate small molecule drug discovery by leveraging EMMI, Terray’s integrated experimental and AI platform. This approach enables rapid, iterative experimentation combining advanced hardware, AI models, and scientific expertise, aiming to streamline the identification and development of new therapies for areas with significant unmet medical need.

About Terray

Terray is a chemistry-first, AI-native biotechnology company founded at the convergence point of machine intelligence, human intellect, and medicine. The company continues to grow its own dataset, refine its own hardware, and train its own AI to turn impossible drug discovery challenges into inevitable small-molecule solutions. The result is an interconnected platform that enables deep collaboration in all areas—between AI and people, chemistry and biology, hardware and software, and data and design.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203259759/en/

Media Contact
Erika Shaffer
Press@terraytx.com

Source: Terray Therapeutics

Key Terms

generative ai technical

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

high-throughput chemical experimentation technical

A laboratory approach that runs many small, automated chemical tests in parallel to quickly find promising molecules or reactions, similar to trying dozens of recipe tweaks at once to see which tastes best. For investors, it matters because it can shorten development time, cut research costs and increase the odds of discovering viable drugs, materials or chemicals—potentially speeding revenue or reducing the financial risk tied to a company’s R&D pipeline.

structure activity data technical

Structure activity data is a set of measurements that links the physical shape and chemical features of molecules to how they perform in biological tests, essentially showing which molecular changes improve or reduce a drug-like effect. For investors, this information signals how advanced and predictable a drug discovery program is — like seeing recipes and taste tests that explain which ingredient changes make a dish better — and it affects prospects for successful development, patent strength, and future value.

small molecule drug discovery technical

The process of identifying and developing small chemical compounds that can act as medicines by binding to biological targets, like designing keys to fit and turn specific locks in the body. Investors care because successful discoveries can become proprietary drugs with large sales potential, but the work is costly, slow and risky—so progress, patent protection and early trial results strongly affect a company’s value.